BCL2 and small cell lung carcinoma: In addition, in small cell lung cancer (SCLC) cells, NF-κB has been suggested to be a downstream target of PI3K p110α since small molecule inhibitors of p110α reduce the expression of NF-κB, resulting in decreases in the expression levels of NF-κB transcriptional targets such as BCL2 and BCL-XL in a SCLC cell line [57].